CervoMed Inc. Income Statement
CRVO|4 years of annual SEC 10-K data (FY2011-FY2025)
Line items include revenue, cost of goods sold, gross profit, operating expenses, interest, taxes, and net income with per-share data across 4 fiscal years. All figures from audited SEC 10-K filings.
CervoMed Inc. reported $4M in revenue and $27M in net loss for FY2025. Revenue has grown at a 14.9% compound annual rate over the past 14 years.
Based on SEC 10-K filings.
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -5.07 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2011 |
|---|---|---|---|---|
| Revenue | $4.0M | $7.1M | $0 | $570.5K |
| Cost of Revenue | - | - | - | $2.3M |
| Gross Profit | - | - | - | -$1.7M |
| SG&A Expense | $10.5M | $6.5M | $2.1M | $6.7M |
| R&D Expense | $21.8M | $8.4M | $1.3M | - |
| Operating Income | -$28.3M | -$7.8M | -$3.5M | -$16.4M |
| Interest Expense | - | - | $587 | $420.7K |
| Income Tax | $0 | - | - | - |
| Net Income | -$27.0M | -$2.2M | -$5.8M | -$15.8M |
| EPS (Basic) | -$2.02 | -$0.82 | -$11.20 | - |
| EPS (Diluted) | - | - | - | -$0.14 |
| Shares Outstanding | 8.7M | 5.7M | 518.1K | 57.7M |
| Gross Margin | - | - | - | -304.7% |
| Operating Margin | -706.2% | -109.3% | - | -2879.9% |
| Profit Margin | -673.1% | -30.4% | - | -2776.1% |